Biontech Se Stock Current Valuation
| 22UA Stock | EUR 114.70 1.30 1.15% |
Valuation analysis of BioNTech SE helps investors to measure BioNTech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that BioNTech's price fluctuation is very steady at this time. Calculation of the real value of BioNTech SE is based on 3 months time horizon. Increasing BioNTech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioNTech stock is determined by what a typical buyer is willing to pay for full or partial control of BioNTech SE. Since BioNTech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioNTech Stock. However, BioNTech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 114.7 | Real 94.65 | Hype 114.7 | Naive 123.1 |
The real value of BioNTech Stock, also known as its intrinsic value, is the underlying worth of BioNTech SE Company, which is reflected in its stock price. It is based on BioNTech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioNTech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BioNTech SE helps investors to forecast how BioNTech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioNTech more accurately as focusing exclusively on BioNTech's fundamentals will not take into account other important factors: BioNTech SE Company Current Valuation Analysis
BioNTech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BioNTech Current Valuation | 29.68 B |
Most of BioNTech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, BioNTech SE has a Current Valuation of 29.68 B. This is 106.66% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Germany stocks is 78.56% lower than that of the firm.
BioNTech Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNTech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNTech could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics of similar companies.BioNTech is currently under evaluation in current valuation category among its peers.
BioNTech Fundamentals
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 | |||
| Profit Margin | 0.56 % | |||
| Operating Margin | 0.68 % | |||
| Current Valuation | 29.68 B | |||
| Shares Outstanding | 242.68 M | |||
| Shares Owned By Insiders | 64.00 % | |||
| Shares Owned By Institutions | 18.41 % | |||
| Price To Earning | 45.99 X | |||
| Price To Book | 2.31 X | |||
| Price To Sales | 2.19 X | |||
| Revenue | 18.98 B | |||
| Gross Profit | 16.07 B | |||
| EBITDA | 15.13 B | |||
| Net Income | 10.29 B | |||
| Cash And Equivalents | 914.9 M | |||
| Cash Per Share | 3.75 X | |||
| Total Debt | 171.6 M | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 2.67 X | |||
| Book Value Per Share | 76.45 X | |||
| Cash Flow From Operations | 889.7 M | |||
| Earnings Per Share | 38.32 X | |||
| Price To Earnings To Growth | 0.04 X | |||
| Target Price | 334.89 | |||
| Number Of Employees | 4 K | |||
| Beta | 0.2 | |||
| Market Capitalization | 30.49 B | |||
| Total Asset | 15.83 B | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 15.83 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in BioNTech Stock
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.